Lu Xue-Chun, Zhu Hong-Li, Yao Shan-Qian, Fan Hui, Zhuang Xiao-Meng, Yang Yang
Department of Gerontological Hematology, General Hospital of PLA, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Jun;13(3):440-2.
The aim of this study was to investigate the curative effect of amifostine (AMF) combined with recombinant human erythropoietin (rhEPO) on the aged patients with myelodysplastic syndrome. Two aged MDS patients (one aged 91; another 86) were treated with amifostine and rhEPO over a period of 4 weeks. The results showed that a short-term curative effect was observed and transfusion interval was prolonged in both patients after 4 week treatment with 5 x 0.4 g AMF plus 3 x 6,000 U rhEPO per week. The reticulocyte count in MDS-RA patient returned to normal at first week of treatment and still remained in normal level for 4 weeks; leukocyte, hemoglobin and platelet values in peripheral blood of MDS-RCMD patient obviousby increased, the abnormally increased reticulocyte value displayed a decrease trend after amifostine plus rh-EPO treatment. In conclusion, amifostine plus rhEPO may have a good therapeutic effect for aged MDS patients, and its clinical long-term curative effect still needs further evaluation.
本研究旨在探讨氨磷汀（AMF）联合重组人促红细胞生成素（rhEPO）对老年骨髓增生异常综合征患者的疗效。两名老年骨髓增生异常综合征患者（一名91岁，另一名86岁）接受了为期4周的氨磷汀和rhEPO治疗。结果显示，每周使用5×0.4 g AMF加3×6000 U rhEPO治疗4周后，两名患者均观察到短期疗效，输血间隔延长。骨髓增生异常综合征-难治性贫血（MDS-RA）患者的网织红细胞计数在治疗第一周恢复正常，并在4周内保持在正常水平；骨髓增生异常综合征-难治性血细胞减少伴多系发育异常（MDS-RCMD）患者外周血中的白细胞、血红蛋白和血小板值明显升高，氨磷汀加rh-EPO治疗后异常升高的网织红细胞值呈下降趋势。总之，氨磷汀加rhEPO可能对老年骨髓增生异常综合征患者有良好的治疗效果，其临床长期疗效仍需进一步评估。
